Company Profile for Novus Therapeutics, Inc.
- 84
Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device combination product being developed as a potential first-in-class treatment option for patients at risk for, or with, otitis media (“OM” or middle ear inflammation with or without infection). Globally, OM affects more than 700 million adults and children every year, with over half of the cases occurring in children under five years of age. OM is one of the most common disorders seen in pediatric practice, and in the United States is a leading cause of health care visits and the most frequent reason children are prescribed antibiotics or undergo surgery. Novus also has a foam-based drug delivery technology (OP0102), which may be developed in the future to deliver drugs into the ear, nasal, and sinus cavities. For more information please visit novustherapeutics.com.
Company: |
Novus Therapeutics, Inc. | ||||
Headquarters Address: |
19900 MacArthur Blvd., Ste 550 | ||||
Irvine, CA 92612 | |||||
Main Telephone: |
+1 (949) 238-8090 | ||||
Website: |
|||||
Ticker/ISIN: |
NVUS(NASDAQ)/US67011N1054 | ||||
Type of Organization: |
Public | ||||
Industry: |
Pharmaceutical | ||||
Key Executives: |
CEO: Gregory J. Flesher | ||||
President: Catherine C. Turkel | |||||
Senior Vice President of Finance and Administration: Jon S. Kuwahara | |||||
Investor Relations |
|||||
Contact: | Timothy McCarthy | ||||
Phone: | +1 (212) 915-2564 | ||||
Email: | |||||
Corporate Contact |
|||||
Contact: | Michael P. Cruse | ||||
Phone: | +1 (949) 238-8090 x706 | ||||
Email: | |||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20190215005600/en/
- VGP en Areim Voltooien Eerste Closing in 50:50 'SAGA' Joint Venture
- Stax benoemt Andrew Keller om toezicht te houden op Technology Market Coverage voor VK en EMEA
- Vastned Belgium: Bekendmaking van de resultaten van de gewone algemene vergadering van aandeelhouders van 24 april 2024
- SulPayments Zwitserland en Gamecash Mexico verenigd onder internationale holdingstructuur om lokaal betalingsaanbod in Latijns-Amerika uit te breiden
- Melexis Q1 2024 resultaten – Omzet van 241.8 miljoen EUR voor het eerste kwartaal
- LANZAJET KONDIGT INVESTERING AAN VAN MICROSOFTS KLIMAATINNOVATIEFONDS, EN KAN ZIJN BEDRIJF VERDER ONTWIKKELEN